CEO: Michael G. Kauffman

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.


Key numbers

Market Capitalization:1069941600
Shares Outstanding: 62790000
Float: 55643807
Next Earning Date:2020-03-11
TTm EPS: -3.424
TTm Dividend Rate:
200 days moving average:10.22
50 days moving average: 17.21
One day percent Change: -9.51



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,